SpectraWAVE, a medical imaging innovator, has secured $50 million in Series B funding led by Johnson & Johnson Innovation and other investors. The investment aims to enhance SpectraWAVE’s 510k-cleared HyperVue™ Imaging System, which offers advanced intravascular imaging capabilities.
Intravascular imaging has gained significant recognition and is now recommended as a key treatment strategy in Europe. Its ability to provide vital insights during coronary stenting has been backed by numerous clinical trials, as published in The Lancet. HyperVue is revolutionizing intravascular imaging by combining DeepOCT and NIRS technologies, optimizing image quality and simplifying procedures.
Eman Namati, Ph.D., CEO of SpectraWAVE indicated that HyperVue is designed to deliver faster, simpler imaging, enabling optimized stenting procedures and improved patient outcomes and that the strong initial U.S. launch reception has spurred this investment, which will drive further commercial expansion.
HyperVue offers exceptional image clarity and depth, allowing physicians to make informed decisions during coronary stenting. Its unique features, such as no-flush catheter prep, efficient pullbacks, and comprehensive AI-driven tools, enhance ease of use and reduce procedural time.
Moreover, SpectraWAVE is developing a wire-free physiology software add-on for HyperVue, empowering physicians to assess pressure drops in the coronaries rapidly. This advancement strengthens SpectraWAVE’s commitment to improving clinical decision-making and driving innovation in coronary artery disease treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
